Clinical trials: Cutaneous Melanoma, Stage II
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Trial name
- NCT03698019
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 815 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
- Trial name
- NCT02155322
- Testing
- Pegylated Interferon Alfa-2b
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Stages III Skin Melanoma, Stages II Skin Melanoma
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its…
- Conditions
- Stages III Skin Melanoma, Stages II Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT01988831
- Testing
- Propranolol hydrochloride
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- University Hospital, Geneva
Malignant Melanoma
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab.
- Trial name
- SENSITIZE (NCT03278665)
- Testing
- 4SC-202 in combination with Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 40 people
- Sponsor
- 4SC AG
Melanoma
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma
- Trial name
- NCT00338130
- Testing
- AZD6244, Temozolomide
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
Melanoma
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard…
- Trial name
- COLUMBUS-AD (NCT05270044)
- Testing
- Encorafenib and Binimetinib
- Where
- 155 sites in Argentina, Australia and 21 more
- Volunteers
- 815 people
- Sponsor
- Pierre Fabre Medicament
Melanoma, Unresectable Metatstatic Cutaneous Melanoma
Use of 852A in Metastatic Cutaneous Melanoma.
Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
- Trial name
- NCT00189332
- Testing
- 852A
- Where
- 8 sites in France, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Pfizer
Brain and Central Nervous System Tumors, Melanoma
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
- Trial name
- NCT00512798
- Testing
- PS-341 (VELCADE), temozolomide, immunoenzyme technique
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Stage IV Melanoma, Recurrent Melanoma
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
RATIONALE: Interferon beta may interfere with the growth of tumor cells. PURPOSE: This phase II trial is studying how well interferon beta works in treating patients with metastatic cutaneous (skin) melanoma or ocular (eye)…
- Trial name
- NCT00085306
- Testing
- recombinant interferon beta
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Cutaneous Melanoma
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
This study evaluates the clinical safety and tolerability, and the immunological effects of local intradermal injection of tremelimumab in patients with clinical stage I/II melanoma patients undergoing a sentinel node biopsy…
- Trial name
- NCT04274816
- Testing
- Tremelimumab
- Volunteers
- 13 people
- Sponsor
- A.J.M. van den Eertwegh
Kidney Cancer, Melanoma (Skin)
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00704938
- Testing
- aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Temozolomide (also known as TMZ) is a chemotherapy drug given by mouth. It is similar to DTIC, the only FDA-approved chemotherapy for melanoma, but because temozolomide is given by mouth, it can be given daily over a long period…
- Trial name
- NCT00591370
- Testing
- Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Stage IV Melanoma
Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
Current therapies for Stage IV Melanoma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Melanoma.
- Trial name
- NCT00003509
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Burzynski Research Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT01989585
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 49 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01217398
- Testing
- bevacizumab, temozolomide, polymorphism analysis
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Institut Curie
Melanoma
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients…
- Trial name
- NCT00861406
- Testing
- Pegylated Interferon-Alfa 2b (PEG Intron), GP-100 Peptide Vaccine
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document…
- Trial name
- NCT00145158
- Testing
- 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Advanced Melanoma, Metastatic Melanoma
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable).
- Conditions
- Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01134614
- Testing
- Ipilimumab, Sargramostim
- Where
- 257 sites in United States
- Volunteers
- 245 people
- Sponsor
- National Cancer Institute (NCI)
Stage II Cutaneous Melanoma
COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study
Melanoma is an aggressive and potentially fatal skin cancer and was the fifth most commonly diagnosed cancer among both men and women in the United States in 2022.
- Trial name
- COPERGRAM1 (NCT07354152)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital